CAR T Cells and T-Cell Therapies for Cancer
JAMA Clinical Reviews
00:00
Understanding Risks and Durability of CAR T-Cell Therapies
This chapter examines the FDA's recent concerns about secondary malignancies linked to CAR T-cell therapies, focusing on both common and rare malignancies. It also explores ongoing research into the durability of treatment benefits and the implications for patients with extensive chemotherapy backgrounds.
Transcript
Play full episode
